Bio-Rad (BIO.B) | Financial Analysis & Statements

Bio-Rad Laboratories, Inc. | Mid-cap | Healthcare

250,08 US$

0,00 %

| Bio-Rad Stock Comparison:

Bio-Rad vs Abbott Laboratories Bio-Rad vs Boston Scientific Bio-Rad vs Masimo Bio-Rad vs Globus Medical Bio-Rad vs Bio-Rad Laboratories Bio-Rad vs S&P 500 | Market

Overview Income Statement Balance Sheet Cash Flow Key Ratios Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 2,6B

Gross Profit 1,4B 53,73 %

Operating Income 269,0M 10,48 %

Net Income -1,8B -71,86 %

EPS (Diluted) -65,36 US$

Balance Sheet Metrics

Total Assets 9,4B

Total Liabilities 2,8B

Shareholders Equity 6,6B

Debt to Equity 0,43

Cash Flow Metrics

Operating Cash Flow -2,2B

Free Cash Flow 266,2M

Revenue & Profitability Trend

Income Statement

Metric	2024	2023	2022	2021	2020
Revenue	2,6B	2,7B	2,8B	2,9B	2,5B
Cost of Goods Sold	1,2B	1,2B	1,2B	1,3B	1,1B
Gross Profit	1,4B	1,4B	1,6B	1,6B	1,4B
Operating Expenses	1,1B	1,1B	1,1B	1,1B	1,0B
Operating Income	269,0M	337,8M	475,1M	500,3M	421,3M
Pre-tax Income	-2,3B	-850,1M	-4,7B	5,4B	4,9B
Income Tax	-498,3M	-212,8M	-1,1B	1,2B	1,1B
Net Income	-1,8B	-637,3M	-3,6B	4,3B	3,8B
EPS (Diluted)	-65,36 US$	-21,82 US$	-121,79 US$	140,56 US$	126,20 US$

Income Statement Trend

Balance Sheet

Metric	2024	2023	2022	2021	2020
Assets
Current Assets	3,0B	3,0B	3,2B	2,0B	2,1B
Non-Current Assets	6,3B	9,3B	10,3B	15,8B	10,8B
Total Assets	9,4B	12,3B	13,5B	17,8B	13,0B
Liabilities
Current Liabilities	467,8M	522,8M	568,7M	680,9M	631,5M
Non-Current Liabilities	2,3B	3,0B	3,3B	3,4B	2,5B
Total Liabilities	2,8B	3,6B	3,9B	4,1B	3,1B
Equity
Total Shareholders Equity	6,6B	8,7B	9,6B	13,7B	9,9B

Balance Sheet Composition

Cash Flow Statement

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income	-1,8B	-637,3M	-3,6B	4,3B	3,8B
Operating Cash Flow	-2,2B	-853,6M	-5,0B	5,6B	5,0B
Investing Activities
Capital Expenditures	-165,5M	-156,5M	-112,6M	-133,7M	-108,5M
Investing Cash Flow	-136,8M	20,2M	-1,2B	-797,4M	-73,3M
Financing Activities
Dividends Paid	-	-	-	-	-
Financing Cash Flow	-238,0M	-444,1M	956,0M	-76,1M	-543,2M
Free Cash Flow	266,2M	218,3M	80,3M	535,7M	476,4M

Cash Flow Trend

Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -3,83

Price to Book 1,03

Price to Sales 2,66

PEG Ratio -0,02

Profitability Ratios

Profit Margin -85,16 %

Operating Margin 9,72 %

Return on Equity -27,52 %

Return on Assets 1,55 %

Financial Health

Current Ratio 5,99

Debt to Equity 20,50

Beta 0,94

Per Share Data

EPS (TTM) -76,53 US$

Book Value per Share 241,72 US$

Revenue per Share 90,53 US$

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
bio.b	6,8B	-3,83	1,03	-27,52 %	-85,16 %	20,50
Abbott Laboratories	232,9B	17,38	4,77	30,65 %	31,89 %	27,09
Boston Scientific	147,6B	72,80	6,64	9,50 %	11,58 %	52,16
Masimo	8,7B	129,16	9,24	-25,07 %	-23,25 %	72,01
Globus Medical	8,0B	43,96	1,95	4,63 %	7,39 %	2,27
Bio-Rad Laboratories	6,2B	-3,47	0,94	-27,52 %	-85,16 %	20,50

Financial data is updated regularly. All figures are in the company's reporting currency.